A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2017
At a glance
- Drugs RRx 001 (Primary) ; Bevacizumab; Irinotecan; Regorafenib
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms ROCKET
- Sponsors EpicentRx
- 02 Jul 2017 Planned End Date changed from 1 May 2018 to 1 Jan 2018.
- 02 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 Jan 2018.
- 02 Jul 2017 Status changed from recruiting to active, no longer recruiting.